Hjem › Atopisk dermatitt (eksem) › Alabama
Kliniske studier for Atopisk dermatitt (eksem) i Alabama
9 studier for Atopisk dermatitt (eksem) søker deltakere på steder i Alabama.
Byer i Alabama
Offisiell studietekst (engelsk)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham
- River Region Dermatology and Laser- Site Number : 8400041, Montgomery
RekruttererObservasjonsstudie
Alder 12 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Birmingham
- Novartis Investigative Site, Birmingham
RekruttererFase 2
Alder 18 til 100 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Birmingham
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 65 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Cahaba Dermatology & Skin Health Center, Birmingham
RekruttererFase 3
Alder 2 til 11 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- AllerVie Clinical Research, Birmingham
- Cahaba Dermatology and Skin Health Center, Birmingham
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07599813A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Birmingham
RekruttererFase 3
6 Months – 11 Years · Alle kjønn · Oppdatert 7. jul. 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham
RekruttererFase 3
Alder 18 til 63 · Alle kjønn · Oppdatert 6. jul. 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Allervie Clinical Research, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. mai 2026 · NCT05995964Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.